Why has Idexx (IDXX) risen 0.5% since the latest earnings report?

Idexx Laboratories (IDXX) has seen a slight increase of about 0.5% since the presentation of its last earnings report, outperforming the S&P 500 index. The crucial question that investors are pondering is whether this positive trend will persist until the upcoming earnings release or if Idexx is due for a downturn. Before examining recent responses from investors and analysts, let’s reflect on the most recent earnings report to gain insights into the key driving factors behind Idexx’s performance.

During the fourth quarter of 2025, Idexx Laboratories reported earnings per share of $3.08, marking an 18% increase from the previous year and surpassing the Zacks Consensus Estimate by 5.17%. Keeping constant-currency comparisons in mind, earnings per share stood at $2.92, representing a 17% improvement from the prior year. The full-year 2025 earnings of $13.08 reflected a robust growth of 22.6% from the 2024 level, exceeding the Zacks Consensus Estimate by 1.2%.

Revenue-wise, Idexx saw a notable 14% year-over-year increase (12% organic) in quarterly revenues, reaching $1.09 billion. This growth was primarily fueled by a 15% reported and 13% organic increase in Companion Animal Group (CAG) revenue, as well as a 12% reported and 10% organic surge in Water revenue. Throughout the full year of 2025, total revenues amounted to $4.30 billion, up 10% from the previous year, driven by a 9% reported and 8% organic growth in CAG Diagnostics recurring revenue, surpassing the Zacks Consensus Estimate by 0.5%.

Despite the positive financial results, shares of Idexx experienced a 1.5% decline in pre-market trading following the earnings announcement. The revenue analysis by segments revealed that the CAG segment reported a revenue surge of 14.7% on a reported basis and 12.8% organically, while the Water segment saw an 11.9% reported and 9.5% organic revenue increase. In comparison, the LPD segment’s revenues rose by 8.5% on a reported basis and 4% organically. However, revenues from the Other segment witnessed a 0.4% decline both on a reported basis and organically.

From a margin performance perspective, Idexx reported a 15.3% increase in gross profit despite a 12.7% rise in cost of revenues. Operating profit rose by 20.6% to $315.6 million, with an operating margin expansion of 152 bps to 28.9%. Furthermore, Idexx’s financial position by the end of the fourth quarter showed cash and cash equivalents of $180.1 million, with cumulative net cash provided by operating activities increasing to $1.18 billion.

Looking ahead, Idexx provided a 2026 outlook forecasting revenues to range from $4,632 million to $4,720 million, implying a 7.6%-9.6% growth on a reported basis and 7%-9% on an organic basis. Full-year earnings per share are expected to be between $14.29 and $14.80, reflecting a growth of 9-13%. While fresh estimates have shown a flat trend in the past month, Idexx currently holds a Growth Score of B and a Momentum Score of D.

In conclusion, Idexx Laboratories continues to demonstrate robust financial performance and anticipates sustained growth in 2026 amidst market uncertainties and challenges. Investors and analysts will closely monitor the company’s progress and strategic initiatives to capitalize on emerging opportunities in the veterinary and diagnostic sectors.